Industry News
Roche's anaemia therapy trial gets underway worldwide
Swiss pharmaceutical giant Roche has begun a massive, 484-centre Phase III trial of its new drug for anaemia associated with chronic kidney disease. [ + ]
Eiffel's Nasdaq view improves as ADR completed
Eiffel Technologies (ASX:EIF) has established a Level 1 American Depository Receipt (ADR) program in a first step towards a possible international listing for the company. [ + ]
BresaGen merger still looks likely
The merger of BresaGen's US-based cell therapy division with San Diego stem cell company Cythera looks like it will go ahead, after the two companies executed the merger agreement last week. [ + ]
Telstra and University combine for future
Telstra has awarded a $950,000 contract to the University of Adelaide's Traffic Research Centre (TRC) Mathematical Modelling unit to develop analysis tools and techniques applicable to network infrastructure that will cater for next generation telephony, broadband data and mobile services.
[ + ]From in vitro to in vivo: Australian biotech grows up
Since last year's BIO, the Australian biotechnology sector has been all about growth, writes Melissa Trudinger. [ + ]
Award for Australian biotechnology pioneer
Australian biotechnology pioneer, Dr Tom Grace, has been awarded the Society for In Vitro Biology's highest honour, the 2004 Lifetime Achievement Award for his contribution to the development of invertebrate in vitro biology.
[ + ]WEHI diabetes researcher honoured
Prof Len Harrison, of the Walter and Eliza Hall Institute, has been awarded the David Rumbough award for scientific excellence by the Juvenile Diabetes Research Foundation International for his research towards finding a cure for type 1 diabetes. [ + ]
Biosignal animal studies show efficacy
Biosignal (ASX:BOS) has confirmed the efficacy of its furanone molecules in preventing bacterial colonisation of contact lenses in animal studies, paving the way for more extensive human studies. [ + ]
Ambri to evaluate SensiDX in hospitals
Ambri (ASX:ABI) has installed its SensiDX System at the Royal North Shore Hospital in Sydney for evaluation and expects to install a second system at Sydney's St Vincent's Hospital shortly. [ + ]
Water savings and hydroponic lettuce
At a time of water restrictions across metropolitan Melbourne and Victoria's farmers crying out for rain, RMIT University researchers are coming up with a bright idea to save water.
[ + ]Evogenix fine-tunes Absalus antibodies in strategic alliance
If you need to give your humanised monoclonal antibodies (MAbs) a gecko-like grip on their therapeutic targets, who do you call? [ + ]
Beam me up: the Synchotron is on its way
Medical researchers in Melbourne were given a brief glimpse this week of the potential of the synchrotron to enhance and expand medical science. [ + ]
New faces at the Bionomics
Adelaide drug-discovery company Bionomics (ASX:BNO, US OTC:BMICY) has appointed Dr Tim Harris, CEO and co-founder of US biotech Structural GenomiX, to its advisory board. [ + ]
Ventracor pilot trial to continue
Sydney-based Ventracor (ASX:VCR) today announced its pilot trial, testing the safety of its VentrAssist artifical heart device, will continue. [ + ]
I’s dotted and t’s crossed on BresaGen restructure
The administrators of Adelaide biotech BresaGen (ASX:BGN) today formalised the agreement the company has made with Queensland-based public unlisted biotech company CBio by executing a Deed of Company Arrangement for the restructure of the company. [ + ]